XNCR (Xencor) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XNCR Xencor Inc XNCR
46 GF Score
Price $19.51
GF Value $9.20
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Xencor FFO?

FFO (Funds from operations) only applies to REITs.

XNCR
46GF Score
Xencor Inc XNCR
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xencor (XNCR) Overvalued in 2026?

Based on GuruFocus' analysis, Xencor stock appears to be overvalued. The current stock price of $19.51 is trading 112.1% above its estimated GF Value™ of $9.20. GuruFocus considers Xencor to be Significantly Overvalued.

Key valuation signals for XNCR:

  • FFO:
  • GF Value™: $9.20 vs. price of $19.51 (112.1% above fair value)
  • GF Score™: 46/100 with 8 warning signs

No single metric tells the full story. See the XNCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xencor Business Description

Other Exchanges XE9:Germany
Address 465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
46GF Score

Get the complete analysis for XNCR

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.51
Price
$9.20
GF Value